InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: hschlauch post# 41064

Sunday, 11/05/2017 1:01:34 AM

Sunday, November 05, 2017 1:01:34 AM

Post# of 48316
The fact that more partial responders are becoming complete responders over a longer period of time is a very good sign. I can't wait to see the full data and patient charts from SITC. With regards to the multi-gene platform, the publication from AACR this past April showed positive results in a mouse model and stated that would be the foundation for future trials.

If PISCES trial is successfull and Merck goes all in, I would not be surprised to see the multi-gene platform exploited to the fullest in indications such as TNBC, Markell Cell, Head and Neck.